To evaluate the differences in protective effect against hypertonic saline inhalation tests between DSCG aerosols (1puff=1mg) and solution (1A=20mg), nine asthmatic children (male 5, female 4, aged 8 to 14 years-old), institutionally hospitalized, had 4 times of 3.5% hypertonic saline inhalation tests. Each inhalation test was performed at 15 minutes after inhalation of normal saline (control), DSCG aerosols (2puff=2mg), DSCG aerosols (4puff=4mg), and DSCG solution (1A=20mg) at the interval of at least more than 2 day and within 7 days. There were no significant differences in %FEV
1.0 immediately before hyperosmolar challenge between groups. The dose of hypertonic saline provoking the 20% decrement in FEV
1.0 (PD
20) was used as the index for protective effect. All DSCG treatments significantly attenuated airway responsiveness to inhaled hypertonic saline as compared to control. Regarding comparisons among DSCG treatments, there was a significant difference in PD
20 between DSCG 2puff and 4puff, while no significant differences between DSCG aerosols and solution were observed. In both DSCG 2puff and 4 puff treatment group, subjects were divided into two groups individually, being responder and non-responder group, whose PD
20 were improved or not by inhaled DSCG aerosols respectively. Values of PD
20 after DSCG 2puff were less than those after DSCG solution and almost similar to those of control in 4 of 5 cases with higher airway hyperresponsiveness, whose PD
20 (control) were less than 2ml.
Those results suggest that although DSCG aerosols could afford similar protective effect as well as DSCG solution in mild cases, DSCG 2puff may not be effective in cases with severe airway hyperresponsiveness. Further studies will be required to evaluate the effect of DSCG aerosols with different clinical severity.
View full abstract